AI-Powered Drug Discovery Platform for Rapid 5 Alpha Reductase Inhibitor Identification
Computational drug discovery platform combining structure-based screening, AI molecular generation, and optimization to rapidly identify 5 alpha reductase inhibitor lead compounds. Reduces time and cost of early-stage drug discovery with a proven track record across 25+ projects.
Overview
This offering provides access to an AI-driven drug discovery platform designed to accelerate the identification of 5 alpha reductase (5AR) inhibitors, which are relevant to treatments for conditions such as benign prostatic hyperplasia and androgen-related disorders. The platform streamlines the early drug discovery pipeline by combining 3D structural analysis of the target enzyme, pocket identification, structure-based drug design (SBDD) screening, AI-based molecular generation, and ADMET optimization. By automating and accelerating these stages, the platform significantly reduces both the time and cost typically required to reach lead compound identification. The system has been applied in more than 25 drug discovery projects, with several producing hits demonstrating activity in the 3–5 nanomolar range.
Technical specifications
Platform capabilities:
- 3D structure selection and binding pocket identification for 5 alpha reductase
- Structure-based drug design (SBDD) virtual screening across large compound libraries
- AI-driven molecular generation producing more than 100 million candidate molecules
- Molecular optimization focused on potency and ADMET properties
- Capability to screen more than 10 billion compounds per project cycle
- Output compounds that are readily available for purchase or low-cost synthesis
Engagement process:
- Free preliminary test to demonstrate platform capability before project commitment
- Iterative screening, synthesis, and activity testing cycles of 20–30 compounds per round
- Activity validation to confirm compound performance
Technology readiness level
The underlying platform is fully operational and has been validated through application in more than 25 drug discovery projects. In several of these projects, the platform has successfully identified hit compounds with activity levels in the 3–5 nanomolar range, demonstrating strong early-stage performance. The platform is ready for immediate deployment in new 5 alpha reductase inhibitor discovery projects, with a free initial test available to prospective partners.
About Zhejiang Shuren University
Zhejiang Shuren University is a private, application-oriented undergraduate university with more than 17,000 full-time students, campuses in Hangzhou and Shaoxing, and a practical, service-oriented character. Its industry model combines school-government-enterprise collaboration, 12 industry colleges, more than 300 external internship and training bases, and joint postgraduate education. Eleven provincial or ministerial research platforms and an Academician Workstation support applied research, while its Yangtze River Delta location connects the university to a dense industrial ecosystem. Funding includes competitive support from the National Natural Science Foundation of China, Ministry of Education programs, and Zhejiang provincial agencies. Research administration supports commissioned work, intellectual property, patent transfer, and commercialization.
delivered to your inbox.